An appeals court has affirmed an earlier decision to uphold two patents related to microfluidic device construction.

The complexity of genomics and lack of standards has made it difficult for labs to report discrete, computable data directly into EHRs for clinical decision support.

The firm is aiming to create pan-organ transplant services that connect patients to doctors throughout the transplant and recovery process.

News items for the week of Oct. 25, 2021.

Jumpcode Genomics has launched two new kits for ribosomal RNA depletion. The CRISPRclean Stranded Total RNA Prep kit with rRNA depletion offers unbiased depletion and library preparation for RNA sequencing. The CRISPRclean Plus kit depletes over 200 bacteria species and human rRNA sequences to enable identification of lower-expressed transcripts.

The director of the Max Planck Institute for the Science of Human History has been demoted after an internal investigation uncovered evidence of workplace misconduct and bullying.

The measures are legally binding for both Illumina and Grail, and compliance with them will be monitored by a trustee to be approved by the commission.

The NIH and grant recipient EcoHealth Alliance are at odds about how the latter reported and handled a potentially high-risk coronavirus study funded by the agency, the WSJ reports.

The test uses RT-LAMP and lateral flow strip technologies to detect the SARS-CoV-2 ORF1ab gene in anterior nasal swabs.

Wired reports on two California condors that appear to have been cases of facultative parthenogenesis.

In Science this week: genetic analysis confirms an individual's claims that he is the great-grandson of Sitting Bull, and more.

Roswell Biotechnologies has formed a scientific advisory board to help with the final stages of development and commercialization of its molecular electronics chips. Members of the SAB include:

• James Tour, professor of chemistry, computer science, and materials science and nanoengineering at Rice University
• Sandra Schmid, CSO of the Chan Zuckerberg Biohub
• Drew Hall, associate professor of electrical and computer engineering at the University of California, San Diego
• Eli Yablanovitch, professor of electrical engineering and computer sciences at the University of California, Berkeley
• George Church, professor of genetics at Harvard Medical School and professor of health sciences and technology at Harvard and MIT
• Stanley Nelson, professor of human genetics, psychiatry, pediatrics, pathology and laboratory medicine at the David Geffen School of Medicine at the University of California, Los Angeles
• Stanley Osher, professor of mathematics, computer science, electrical engineering, and chemical and biomolecular engineering at UCLA

The firm reported increased demand in clinical diagnostics attributed to higher utilization of lab operations as businesses recover from the COVID-19 pandemic.

Despite decreases in COVID-19 testing volume, the firm saw an increase in clinical and genomic test revenue.

The molecular diagnostics company reported $75.6 million in revenues for the quarter and said testing service revenues rose 46 percent year over year.

The molecular residual disease test from Natera was first made available to biopharmaceutical customers and clinicians across China in June.

The company recently presented new results on the test's sensitivity and specificity, as well as its performance across specific nodule sizes and cancer stages.

The firm strengthened its Cor this week by announcing two new assays for the high-throughput, automated system.

Using Oxford Nanopore's MinIon to sequence molecules about 500 bp long, researchers were able to detect copy number aberrations in AML.

Researchers from the UK used integrated genomics to analyze prospectively collected samples from metastatic clear cell renal cell carcinoma patients.

A public-private partnership plans to speed the development of gene therapies for rare genetic diseases, Stat News writes.

The Wall Street Journal reports Eli Lilly has initiated a rolling submission to the US Food and Drug Administration to seek approval for its drug to treat Alzheimer's disease.

Science reports that a 2014 DNA barcoding paper was retracted after a co-author brought up data validity concerns.